Tirzepatide, as a dual GIP and GLP-1 receptor agonist, acts on both incretin pathways with even broader receptor engagement than semaglutide, raising questions about downstream effects on neurotransmitter systems beyond glucose and appetite regulation
As the first GLP-1 pill approved for weight loss, oral semaglutide offers a flexible, medically guided option that supports long-term weight management through personalized care and patient choice
doi: 10.1530/JME-13-0208
However, if you are taking a GLP-1 medication and experience symptoms such as abdominal pain or discomfort, it's important to speak to your doctor
Administer as Directed:Only inject or infuse the resultant solution per your providers or medications guidelines
So we're not, so we published on 47, but I need a follow up with, with hun, I mean, hundreds of patients using it now